Market Research Report
Febrile Neutropenia Market: By Therapeutics Molecule Type (Pegfilgrastim, Vancomycin hydrochloride, Filgrastim biosimilars, Pegfilgrastim biosimilars, Stimuxen and Others) & By Region (North America, Europe, Others)-Forecast 2019-2024
|Published by||IndustryARC||Product code||421921|
Delivery time: 2-3 business days
|Febrile Neutropenia Market: By Therapeutics Molecule Type (Pegfilgrastim, Vancomycin hydrochloride, Filgrastim biosimilars, Pegfilgrastim biosimilars, Stimuxen and Others) & By Region (North America, Europe, Others)-Forecast 2019-2024|
|Published: December 26, 2018||Content info:||
Febrile neutropenia is the development of fever with signs of infection and is one of the most severe complications during cancer chemotherapy. It is mainly caused by infectious agents such as gram positive and gram negative bacteria. This results in significant reduction of white blood cell count in the patients. Blood test is used to determine the number of white blood cells and to diagnose febrile neutropenia disease. Apart from blood tests, febrile neutropenia is treated through administration of prophylactic antibiotics to recover from persistent fever conditions.
The market of febrile neutropenia is majorly driven by innovative new product developments and procedures by the key players. Positive initiatives by North American and European governments will further drive the market growth of febrile neutropenia. However, lack of specific treatment for all the symptoms of this disorder may hamper the growth of this market. The market has also witnessed a high competition which eventually results in price reduction.
This report identifies the global febrile neutropenia market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Febrile Neutropenia market.
Geographically, North America is estimated to be the largest market owing to a large pool of patients followed by Europe. It is estimated that Asia-Pacific will witness the highest growth owing to increasing awareness and new product development during the forecast period.
Febrile Neutropenia Market, by Therapeutics Molecule Type: Pegfilgrastim, Vancomycin hydrochloride, Filgrastim biosimilars, Pegfilgrastim biosimilars, Stimuxen, and Others
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.
Xenetic Biosciences plc
Aequus BioPharma, Inc.
More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"